Blog Posts

Arndt Vogel: Neratinib alone has no effect, but are the combinations promising?

Arndt Vogel/X

Apr 3, 2025, 09:59

Arndt Vogel: Neratinib alone has no effect, but are the combinations promising?

Arndt Vogel, Director of the Center for Personalized Medicine at Hannover Medical School, shared a post on X about recent paper by Ghassan K. Abou-Alfa et al.:

“Neratinib Alone or in Combination with Immune Checkpoint Inhibitors with or without mTOR Inhibitors in Fibrolamellar Carcinoma Liver Cancer

Not sure what to conclude… Neratinib alone has no effect, but are the combinations promising?”

Authors: Ghassan K. Abou-Alfa et al.

Arndt Vogel

Albert S. Cornelius Alison Clemens O'Neill Amin Yaqubie Arndt Vogel cancer Crystal S. Denlinger Daniel DiPrimeo David B. Solit Eileen M. O'Reilly fibrolamellar carcinoma Ghassan K. Abou-Alfa James J. Harding John D. Gordan Joseph S. Light Lisa D. Eli liver cancer OncoDaily Oncology Pablo Cano Raed Al-Rajabi Richard Kinh Gian Do Sarina A Piha-Paul Scott Sherrin Tim Meyer

Neil Ranasinghe: What’s the Difference Between a Clinician and a Technical Author?

LOCKTAC Molecular Glues Are Changing the Rules of Drug Discovery - Amgen

Top 10 Immunotherapy Trials in Lung Cancer to Watch at ESMO 2025

FDA has Granted Full Market Approval for Papzimeos - NIH

Kirsty Duncan։ Thirty-two Months Into Fighting Cancer...